KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Accounts Payables (2016 - 2025)

Historic Accounts Payables for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $33.6 billion.

  • AbbVie's Accounts Payables rose 1025.51% to $33.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $33.6 billion, marking a year-over-year increase of 1025.51%. This contributed to the annual value of $31.9 billion for FY2024, which is 422.51% up from last year.
  • According to the latest figures from Q3 2025, AbbVie's Accounts Payables is $33.6 billion, which was up 1025.51% from $32.2 billion recorded in Q2 2025.
  • In the past 5 years, AbbVie's Accounts Payables ranged from a high of $33.6 billion in Q3 2025 and a low of $20.6 billion during Q1 2021
  • Its 5-year average for Accounts Payables is $27.0 billion, with a median of $27.0 billion in 2023.
  • As far as peak fluctuations go, AbbVie's Accounts Payables skyrocketed by 6212.13% in 2021, and later plummeted by 90.98% in 2025.
  • Over the past 5 years, AbbVie's Accounts Payables (Quarter) stood at $22.7 billion in 2021, then increased by 11.91% to $25.4 billion in 2022, then rose by 20.66% to $30.6 billion in 2023, then rose by 4.23% to $31.9 billion in 2024, then rose by 5.24% to $33.6 billion in 2025.
  • Its last three reported values are $33.6 billion in Q3 2025, $32.2 billion for Q2 2025, and $31.0 billion during Q1 2025.